Synthesis and evaluation of cyclic diamino benzamide based D3 receptor ligands

Benjamin E. Blass; Peng Jen Chen; Michelle Taylor; Suzy A. Griffin; John C. Gordon; Robert R. Luedtke

doi:10.1007/s00044-021-02845-z

Synthesis and evaluation of cyclic diamino benzamide based D₃ receptor ligands

Benjamin E. Blass, Peng Jen Chen, Michelle Taylor, Suzy A. Griffin, John C. Gordon, Robert R. Luedtke

Research output: Contribution to journal › Article › peer-review

Abstract

Dopamine (1) is a key neurotransmitter whose impact on pharmacological processes is mediated by a family of dopamine receptors designated D₁, D₂, D₃, D₄, and D₅. Various diseases and conditions such as schizophrenia, drug abuse, depression, restless leg syndrome, Parkinson’s disease (PD), and inflammatory diseases have been linked to aberrant D₃ activity. Herein, we report a series of novel D₃ ligands with improved solubility over our previous lead compound, MC25-41 (2).[Figure not available: see fulltext.]

Original language	English
Pages (from-to)	446-461
Number of pages	16
Journal	Medicinal Chemistry Research
Volume	31
Issue number	3
DOIs	https://doi.org/10.1007/s00044-021-02845-z
State	Published - Mar 2022

Keywords

D dopamine receptor
D dopamine receptor
Dopamine

Access to Document

10.1007/s00044-021-02845-z

Cite this

@article{ecf1dadf419a4eb1bed4f529f477a51d,

title = "Synthesis and evaluation of cyclic diamino benzamide based D3 receptor ligands",

abstract = "Dopamine (1) is a key neurotransmitter whose impact on pharmacological processes is mediated by a family of dopamine receptors designated D1, D2, D3, D4, and D5. Various diseases and conditions such as schizophrenia, drug abuse, depression, restless leg syndrome, Parkinson{\textquoteright}s disease (PD), and inflammatory diseases have been linked to aberrant D3 activity. Herein, we report a series of novel D3 ligands with improved solubility over our previous lead compound, MC25-41 (2).[Figure not available: see fulltext.]",

keywords = "D dopamine receptor, D dopamine receptor, Dopamine",

author = "Blass, {Benjamin E.} and Chen, {Peng Jen} and Michelle Taylor and Griffin, {Suzy A.} and Gordon, {John C.} and Luedtke, {Robert R.}",

note = "Funding Information: The research reported in this publication was supported by the National Institute on Drug Abuse (NIDA)/National Institutes of Health (NIH) under award numbers DA029840-06A1 and DA023957. Publisher Copyright: {\textcopyright} 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.",

year = "2022",

month = mar,

doi = "10.1007/s00044-021-02845-z",

language = "English",

volume = "31",

pages = "446--461",

journal = "Medicinal Chemistry Research",

issn = "1054-2523",

publisher = "Birkhauser Boston",

number = "3",

}

TY - JOUR

T1 - Synthesis and evaluation of cyclic diamino benzamide based D3 receptor ligands

AU - Blass, Benjamin E.

AU - Chen, Peng Jen

AU - Taylor, Michelle

AU - Griffin, Suzy A.

AU - Gordon, John C.

AU - Luedtke, Robert R.

N1 - Funding Information: The research reported in this publication was supported by the National Institute on Drug Abuse (NIDA)/National Institutes of Health (NIH) under award numbers DA029840-06A1 and DA023957. Publisher Copyright: © 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

PY - 2022/3

Y1 - 2022/3

N2 - Dopamine (1) is a key neurotransmitter whose impact on pharmacological processes is mediated by a family of dopamine receptors designated D1, D2, D3, D4, and D5. Various diseases and conditions such as schizophrenia, drug abuse, depression, restless leg syndrome, Parkinson’s disease (PD), and inflammatory diseases have been linked to aberrant D3 activity. Herein, we report a series of novel D3 ligands with improved solubility over our previous lead compound, MC25-41 (2).[Figure not available: see fulltext.]

AB - Dopamine (1) is a key neurotransmitter whose impact on pharmacological processes is mediated by a family of dopamine receptors designated D1, D2, D3, D4, and D5. Various diseases and conditions such as schizophrenia, drug abuse, depression, restless leg syndrome, Parkinson’s disease (PD), and inflammatory diseases have been linked to aberrant D3 activity. Herein, we report a series of novel D3 ligands with improved solubility over our previous lead compound, MC25-41 (2).[Figure not available: see fulltext.]

KW - D dopamine receptor

KW - Dopamine

UR - http://www.scopus.com/inward/record.url?scp=85124157593&partnerID=8YFLogxK

U2 - 10.1007/s00044-021-02845-z

DO - 10.1007/s00044-021-02845-z

M3 - Article

AN - SCOPUS:85124157593

SN - 1054-2523

VL - 31

SP - 446

EP - 461

JO - Medicinal Chemistry Research

JF - Medicinal Chemistry Research

IS - 3

ER -

Synthesis and evaluation of cyclic diamino benzamide based D₃ receptor ligands

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this